Non-peptidic glucose-like peptide-1 receptor agonists: aftermath of a serendipitous discovery

@inproceedings{Wang2010NonpeptidicGP,
  title={Non-peptidic glucose-like peptide-1 receptor agonists: aftermath of a serendipitous discovery},
  author={Ming-wei Wang and Qing Liu and Cai-hong Zhou},
  booktitle={Acta Pharmacologica Sinica},
  year={2010}
}
Glucagon-like peptide-1 (GLP-1) receptor is an ideal target in the development of incretin-based therapies for diabetes and obesity. Two approaches have been adopted: GLP-1 receptor agonists that mimic the effects of native GLP-1 and dipeptidyl peptidase-4 inhibitors that increase endogenous GLP-1 levels. During the past two decades, search for orally active, non-peptidic GLP-1 receptor agonists has been the focal point of research and development activities in many multinational pharmaceutical… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-7 of 7 extracted citations

The role of serum albumin in the metabolism of Boc5: molecular identification, species differences and contribution to plasma metabolism.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences • 2013
View 6 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 34 references

Degradation of glucose

TJ Kieffer, CH McIntosh, RA. Pederson
risk, and treatment goals. Postgrad Med • 2010

Prevalence of diabetes among men and women in China

Z Shi
N Engl J Med • 2010

Prevalence of diabetes among men and women in China.

The New England journal of medicine • 2010

A kind of receptor signaling transduction positive modulators, preparation methods and uses thereof

MW Wang, YY Yuan, +3 authors LD Gao
WO Patent 2009129696 • 2009

Oxadiazoanthracene compounds for the treatments of diabetes

AM Mjalli, DR Polisetti, +3 authors C Behme
WO Patent 2009111700 • 2009

Similar Papers

Loading similar papers…